Catalent to buy Paragon Bioservices for $1.2 bln -WSJ
April 14 (Reuters) - Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.
An all-cash deal between the companies is expected to be announced on Monday morning, the Journal said https://www.wsj.com/articles/contract-drug-manufacturer-catalent-to-buy-paragon-bioservices-in-1-2-billion-deal-11555277951?mod=searchresults&page=1&pos=2. (Reporting by Ismail Shakil in Bengaluru Editing by Chris Reese)
Terms and Privacy Policy